[Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
The effects of the hepatoprotective, antioxidant drug silymarin (Legalon) on some cellular immune parameters of patients with histologically proven chronic alcoholic liver disease were studied in a six month double blind study. The lectin induced proliferative activity of the lymphocytes got enhanced, the originally low T cell percentage and the originally high CD8+ cell percentage have been normalized, the antibody-dependent and natural cytotoxicity of the lymphocytes decreased during silymarin therapy. All these changes were significant, while in the placebo group no significant changes occurred, except for a moderate elevation of the T cell percentage. Thus, the immunomodulatory activity of silymarin might be involved in the hepatoprotective action of the drug and improves the depressed immunoreactivity of the patients.
Deák
G
G
Semmelweis Orvostudományi Egyetem, II. sz. Belklinika, Budapest.
Müzes
G
G
Láng
I
I
Niederland
V
V
Nékám
K
K
Gonzalez-Cabello
R
R
Gergely
P
P
Fehér
J
J
D000276:Adjuvants, Immunologic; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012838:Silymarin / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D005419:Flavonoids; D012838:Silymarin
Silymarin kezelés immunmoduláns hatása krónikus alkoholos májbetegségben.